_640x250.jpg)
Partnering
Matisse Pharmaceuticals has built a network of strategic partners to achieve its goals. We aim to extend this network further, as we strongly believe that important goals can only be reached in collaboration. Feel free to contact us any time in case you believe you can add value to Matisse in achieving its mission to save millions of lives by effectively combating extracellular cytotoxic histones.
University of Maastricht / MUMC+
Matisse Pharmaceuticals BV has obtained a worldwide exclusive and transferable license from Maastricht University (MU) and Maastricht University Medical Centre (MUMC+) for commercializing M6229 and Next Generation M6229. The University of Maastricht is supporting Matisse in further research and pre-clinical activities. The MUMC+ is also taking part in the multicenter Histoseps clinical study led by AUMC.
AUMC
Matisse Pharmaceuticals is working closely together with the Amsterdam University Medical Center for the investigator driven Histoseps Phase I/IIa clinical dose escalation study with M6229 in septic patients in the Intensive Care Unit (ICU).
Basic Pharma
For the CMC part of the development, such as drug substance process development, galenic development, analytics, IMP manufacture and regulatory affairs, Matisse Pharmaceuticals can rely on the expertise and facilities offered by the Basic Pharma Group.
Partnering
Matisse Pharmaceuticals has built a network of strategic partners to achieve its goals. We aim to extend this network further, as we strongly believe that important goals can only be reached in collaboration.
Feel free to contact us any time in case you believe you can add value to Matisse in achieving its mission to save millions of lives by effectively combating cytotoxic histones. Contact us